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Abstract
Background: The Raf kinase inhibitor protein (RKIP) has been shown to block MAP kinase
pathway as well as NFκB signalling. By means of immunohistochemistry, we previously
demonstrated that the MAP kinase pathway is virtually inactive in Merkel cell carcinoma (MCC).
Similarly to MCC in situ high RKIP expression accompanies absence of ERK phosphorylation in the
MCC cell line UISO suggesting that RKIP might be causative for MAP kinase pathway silencing.
Methods: Applying an siRNA approach RKIP expression was knocked down in UISO cells and a
possible influence on MAP kinase pathway activity was assessed by Western blot analysis using
phospho-specific antibodies. Moreover, a possible effect of RKIP knock down in UISO cells on
proliferation as well as chemosensitivity to cisplatin were examined applying the MTS assay.
Results: Surprisingly the absence of phosphorylation of the MAP kinases ERK1 and ERK 2 even
following growth factor stimulation was not affected by the RKIP knock down indicating that RKIP
is not essential for blocking the MAP kinase pathway in the MCC cell line UISO. Moreover,
proliferation as well as chemosensitivity towards cisplatin were not altered upon knock down of
RKIP.
Introduction
Merkel cell carcinoma (MCC) is a highly aggressive skin
cancer of neuroendocrine origin [1]. The tumors com-
monly affect elderly patients and are frequently located in
body areas that are chronically sun exposed [2]. The
genetic and molecular mechanisms involved in the devel-
opment and progression of MCC are largely unknown.
A signal transduction pathway that is activated in many
tumor entities is the MAP kinase pathway, a major regula-
tor of cell growth, differentiation and survival. It com-
prises the three consecutive kinases Raf, MEK (MAP kinase
kinase) and ERK (p42/p44 MAP kinases) which are con-
trolled by the small G-Protein Ras [3]. Recently, we dem-
onstrated by immunohistological analysis of 49 MCC
tumors for expression and phosphorylation of ERK that
the MAPK pathway is virtually inactive in MCC [4]. This
inactivity is preserved in the MCC cell line UISO and acti-
vation of the MAPK pathway by an inducible Raf kinase in
UISO cells induces apoptosis [5], possibly explaining why
the pathway is generally shut off in MCC. A negative reg-
ulator of the MAP kinase pathway which can bind either
to Raf or to MEK and thereby interfere with the activation
of MEK is the Raf Kinase Inhibitor Protein (RKIP) [6]. In
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MCC  in situ the absence of MAP kinase activation is
accompanied by high level expression of RKIP [4].
Materials and methods
Cell culture
The MCC cell line UISO, which has been established from
a primary Merkel cell carcinoma of a 46 year old woman
[7], was grown in RPMI 1640 supplemented with 10%
FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin.
siRNA transfection
An Alexa Fluor 488 labelled scrambled siRNA as negative
control (AAT TCT CCG AAC GTG TCA CGT) as well as an
siRNA targeting RKIP (AAG GTG GCG TCC TTC CGT
AAA) [8] were purchased from Qiagen (Hilden, Ger-
many). 1.4 × 105 UISO cells were seeded in 24 well plates
the day prior to transfection. Two different transfection
reagents were used. The siRNA were transfected at 80 nM
(Lipofectamine 2000; Invitrogen, Karlsruhe, Germany) or
10 nM (HiPerFect; Quiagen, Hilden, Germany) concen-
tration according to the manufacturer's protocols.
Proliferation and chemosensitity measured by the MTS 
assay
24 hours following siRNA transfection the cells were har-
vested with Trypsin/EDTA and were seeded with an equiv-
alent of 2000 cells/well corresponding to the initial cell
number in 96 well plates. For measurement of chemosen-
sitivity cisplatin was added at this time point. To extend
the period of high siRNA levels in the cells a second trans-
fection using HiPerFect (Quiagen) was performed on day
3 following the first transfection. Another 3 days later pro-
liferation and cell viability were assessed by the MTS assay
(CellTiter 96® AQueous One Solution Cell Proliferation
assay, Promega Corporation, Madison, WI, USA). To this
end, 10 µl of CellTiter 96® AQueous One Solution Reagent
containing a tetrazolium compound (MTS) were added to
each well and the cells were incubated for approximately
90 min at 37°C. Metabolically active, viable cells convert
MTS into a colored formazan product that was measured
in a spectrophotometric microplate reader (Perkin-Elmer
Inc., MA, USA) at 493 nm.
Western blot analysis
For protein analysis cells were lysed using Laemmli buffer.
Cell lysates were resolved by SDS-Polyacrylamid gel elec-
trophoresis and transferred to nitrocellulose membranes.
Following blocking for 1 h with phosphate-buffered
saline containing 0.05% Tween 20 and 5% powdered
skim milk, blots were incubated for 2 h or overnight with
primary antibody, washed three times with phosphate-
buffered saline supplemented with 0.05% Tween 20, and
then incubated with the peroxidase coupled secondary
antibody. The bands were detected using a chemo lumi-
nescence detection kit (Roche Diagnostics, Mannheim,
Germany). The antibodies used were the monoclonal
antibodies  α-Phospho-p44/42 MAP kinase (Thr202/
Tyr204) (clone E10; Cell Signaling, Beverly, USA), α-β-
tubulin (Sigma, Ottobrunn, Germany) and the polyclonal
antibody α-RKIP (Upstate, Charlottesville, USA).
Results and discussion
The MCC cell line UISO displays the same MAP kinase
pathway phenotype as it is observed for Merkel cell carci-
noma in situ, in particular the complete lack of ERK 1/2
phosphorylation associated with high expression of RKIP
[4]. Remarkably, ERK remains unphosphorylated even
after growth factor stimulation. We therefore speculated
that the MAP kinase pathway may be kept silent through
the action of RKIP, which can interfere with either the acti-
vation of C-Raf or with the activation of MEK by B-Raf or
C-Raf [6,8]. Consequently, we used an RKIP knock down
approach to test this notion. Using two different reagents
for transfection of UISO cells with an siRNA targeting
RKIP, in both cases greatly reduced RKIP protein levels
compared to cells transfected with an scrambled siRNA
not targeting any mRNA encoded by the human genome.
Strikingly, this knock down however, did not induce any
detectable phosphorylation of ERK (Figure 1). Even upon
prolonged exposure of the films absolutely no phospho-
ERK signal was detectable. When cells are starved from
RKIP knock down in UISO cells does not result in ERK phos- phorylation Figure 1
RKIP knock down in UISO cells does not result in ERK 
phosphorylation. UISO cells were transfected either with a 
scrambled siRNA (S) as negative control or with an siRNA 
targeting RKIP (R). Two different transfection reagents (i.e. 
Lipofectamine 2000 (L) and HiPerfect (H)) were used. 72 h 
following transfection total cell lysates were analysed by 
western blot using a phospho-ERK specific antibody. 
Untransfected MCC13 cells served as positive control (C) 
for ERK phosphorylation and probing for β-tubulin was used 
to visualize protein loading.Journal of Carcinogenesis 2007, 6:16 http://www.carcinogenesis.com/content/6/1/16
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growth factors e.g. by FCS deprivation and are then re-
stimulated, a very strong transient activation of ERK is
observed (Figure 2A). Even under such conditions the
RKIP knock down did not result in a detectable ERK phos-
phorylation. Therefore, the level of RKIP expression is not
critical for the inactivity of the MAP kinase pathway in
MCC cells.
The importance of the Ras/Raf/MEK/ERK signalling path-
way for carcinogenesis is reflected by the facts that Ras
genes are the most frequently mutated oncogenes
detected in human cancer [9,10] and that B-Raf is acti-
vated in several malignancies with the highest frequency
found in melanoma [11]. In MCC, however, we and oth-
ers did not detect any B-Raf or Ras mutations [4,12,13].
In contrast, in MCC in situ as well as in the MCC cell line
UISO MAP kinase pathway activity as measured by ERK
phosphorylation is not detectable at all (Houben et al,
2006). Since activation of the MAP kinase pathway in
UISO cells induces apoptosis [5], demonstrating that this
is a negative selection factor for these MCC cells, it is plau-
sible that inactivity has to be tightly regulated. In the
UISO cells as well as in the MCC tissues, the lack of MAPK
signalling is associated with high expression of the Raf
kinase inhibitor protein (RKIP) [4]. RKIP is a molecule
which was shown to block both MAP kinase pathway as
well as NFκB signalling [14]. Therefore, it was tempting to
speculate whether RKIP might be causative for MAPK
pathway inactivity in MCC cells. Our observation, how-
ever, that even the almost complete reduction in RKIP
protein expression by means of RNAi does not lead to ERK
phosphorylation argues against this model. Still, RKIP is
thought to interfere with the above mentioned signal
transduction pathways by directly binding to particular
pathway proteins. In case of the MAPK pathway, RKIP was
shown to bind B-Raf and c-Raf as well as MEK and thereby
inhibiting the Raf/MEK interaction [6]; in case of the
NFκB pathway, NFκB-inducing kinase and transforming
growth factor beta-activated kinase-1 are the targets.
Therefore, the relative stochiometry of RKIP, not bound to
other targets, and Raf/MEK should be critical for the abil-
ity of RKIP to completely block Raf mediated MEK activa-
tion. Moreover, RKIP itself is regulated by
phosphorylation through Protein kinase C and only
unphosphorylated RKIP binds to Raf [15]. Consequently,
the absolute expression level of RKIP is only one parame-
ter for RKIP activity. However, we recently demonstrated
that MAPK pathway signalling is induced both in UISO-
BXB-ER cells by activating a hormone regulatable Raf
kinase and in UISO cells by the Raf activating agent
ZM336372 [5]. Together with the observation that ERK
phosphorylation in UISO cells cannot be induced by
RKIP knock down in UISO cells does not alter proliferation  properties or chemosensitivity Figure 3
RKIP knock down in UISO cells does not alter prolif-
eration properties or chemosensitivity. A first siRNA 
transfection was performed in 24 well plates with the indi-
cated siRNA. 24 following transfection cells were split to 96 
well plates and cisplatin was added as indicated. A second 
siRNA transfection was performed on day 3 following the 
first transfection. On day 6 proliferation and apoptosis were 
assessed using the MTS assay. Relative extinctions were cal-
culated with the scrambled/no cisplatin sample set to 100%. 
Given are the mean values (± SD) of three independent 
experiments.
RKIP knock down in UISO cells does not confer serum  responsiveness of the MAPK pathway Figure 2
RKIP knock down in UISO cells does not confer 
serum responsiveness of the MAPK pathway. (A) 
NIH3T3 cells were cultured either in the presence of 10% 
FCS, or for 24 hours in the absence of FCS (starved), or 
were re-stimulated with 10% FCS for 20 min following star-
vation. Total cell lysates were subjected to Western Blot 
analysis and probed with the indicated antibodies. (B) UISO 
cells were transfected either with a scrambled siRNA (S) as 
negative control or with a siRNA targeting RKIP. Cells were 
harvested 72 hours later or when indicated FCS was with-
drawn after 48 hours and following 24 hours of starvation 
the cells were restimulated with 10% FCS for the indicated 
time. Total cell lysates were subjected to Western Blot anal-
ysis and probed with the indicated antibodies. As positive 
control for phospho-ERK a lysate from the melanoma cell 
line SKmel-28 was used.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Carcinogenesis 2007, 6:16 http://www.carcinogenesis.com/content/6/1/16
Page 4 of 4
(page number not for citation purposes)
growth factor stimulation [4], these findings suggest that
silencing of the MAPK pathway in MCC cells occurs
upstream or at the level of Raf, hence it further argues
against RKIP being responsible for the observed MAPK
pathway inactivity in MCC.
RKIP has been reported to be involved in the regulation of
proliferation and apoptosis [16-18]. However, in these
cases the effects of RKIP up- or down-regulation on
growth or survival were always accompanied by changes
in MAPK pathway signalling. Therefore we asked whether
in UISO cells the level of RKIP protein expression might
influence proliferation or apoptosis in a MAPK pathway
independent fashion. To this end, we assessed prolifera-
tion of UISO cells following siRNA knock down of RKIP
by means of the MTS assay. This analysis revealed essen-
tially no differences between the cells in which RKIP was
silenced or not (Figure 3, the first two columns). In order
to test the impact of RKIP silencing on apoptosis in
response to genotoxic stress cells were incubated with var-
ying amount of cisplatin. Titration of this cytotoxic drug
to the cells resulted in an increase of dead cells in the cul-
ture (data not shown) and in reduced signals in the MTS
assay. However, again no differences were detectable
whether RKIP expression was knocked down or not. Since
the knock down of RKIP in UISO cells is not associated
with elevation of ERK phosphorylation these findings
support the view that the growth inhibiting and the apop-
tosis suppressing functions observed in other model sys-
tems can be attributed to the ability of RKIP to regulate
MAPK pathway signalling [16].
In summary our data suggest that RKIP expression in the
cell line UISO is not critical for inactivity of the MAPK
pathway, proliferation properties and sensitivity of these
MCC cells towards apoptosis inducing agents.
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